Alicia's Insights in the world of Diabetes: Glucagon: the new wave of diabetes innovation?
Alicia's Insights in the world of Diabetes: Optimization workarounds for the Tandem Control IQ system
Things to remember as we head into a summer like no other. Spending the summer with COVID 19.
As people with diabetes, we can’t become fixated on the math. But, I have some eye-opening realities about the numbers we should become focused on.
We take an in-depth look at the benefits and risk factors of statin use for people with type 1 diabetes.
Springtime...It's a great time to check your diabetes technology coverage options!
We wanted to let you know about a recent acronym change you will be seeing from the educators at IDS.
Novonordisk announced an additional indication for their GLP-1 medications Ozempic to “reduce the risk of major adverse cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease."
A new study discusses the correlation between type 1 and 2 diabetes and cancer and identifies which has more risk.
2 weeks on Control IQ – too soon to call? Our newest Hybrid Closed Loop showing a lot of promise… if you know how to work it.
How the holidays can be a great time for diabetes awareness.
Diabetes Management: Saving up for a rainy day, could leave you out in the storm.
Murphy's Law: Whatever can go wrong, will go wrong
Baqsimi Nasal glucagon gives people with diabetes a new option, but don’t abandon the needle!
FDA approves Eyelea in all forms of Diabetes related retinopathy